SMOLDERING SYSTEMIC MASTOCYTOSIS
Clinical trials for SMOLDERING SYSTEMIC MASTOCYTOSIS explained in plain language.
Never miss a new study
Get alerted when new SMOLDERING SYSTEMIC MASTOCYTOSIS trials appear
Sign up with your email to follow new studies for SMOLDERING SYSTEMIC MASTOCYTOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for mastocytosis patients: expanded access to bezuclastinib
Disease control AVAILABLEThis program provides the investigational drug bezuclastinib to adults with systemic mastocytosis who have failed or cannot tolerate standard treatments. Participants must be at least 18 years old and able to swallow tablets. The goal is to offer a potential treatment option when…
Matched conditions: SMOLDERING SYSTEMIC MASTOCYTOSIS
Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill aims to tame rare mast cell disease
Disease control Recruiting nowThis study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…
Matched conditions: SMOLDERING SYSTEMIC MASTOCYTOSIS
Phase: PHASE2, PHASE3 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC